What does this research mean for the field?

Short-term abciximab treatment provides prolonged platelet inhibition for up to 15 days through continuous reequilibration among circulating platelets, which explains the gradual recovery of platelet function and long-term prevention of ischemic complications. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to establish the pharmacodynamic profile and platelet-bound life span of abciximab.

May 5, 1998Circulation

Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade

View Full Paper

Ask AI

Bookmark

Why the study?

Do different infusion regimens of abciximab (EPIC vs EPILOG) affect its pharmacodynamic profile and platelet-bound life span in individuals?

Population

41 individuals

Comparison

Abciximab 0.25-mg/kg bolus and a 12-hour… vs Abciximab 0.25-mg/kg bolus and a 12-hour…

Design

RCT, randomized

Follow-up

15 days

Authors

MMMary Ann MascelliChinook Regional Hospital ELEllen T. LanceIndianapolis Zoo LDLakshmi DamarajuJanssen (Switzerland)

Discussion

Member takes

Implication

Supports flexible abciximab dosing in PCI; extends evidence for reequilibration enabling inhibition beyond normal platelet lifespan.

Key Points

The study aims to establish the pharmacodynamic profile and platelet-bound life span of abciximab.
41 individuals were randomized to receive abciximab via either the EPIC or EPILOG regimen.
Platelet aggregation and GP IIb/IIIa receptor blockade were measured alongside platelet-bound abciximab monitoring by flow cytometry.
Median relative fluorescence intensity was assessed at 8 and 15 days post-treatment.
Both EPIC and EPILOG regimens exhibited equivalent blockade of GP IIb/IIIa and platelet aggregation.
At 8 days post-treatment, median intensity indicated 29% GP IIb/IIIa receptor blockade; at 15 days, it was 13%.
Fluorescence histograms maintained unimodal profiles, indicating gradual recovery of platelet function.

Structured PICO

Do different infusion regimens of abciximab (EPIC vs EPILOG) affect its pharmacodynamic profile and platelet-bound life span in individuals?

Population

41 individuals

Intervention

Abciximab 0.25-mg/kg bolus and a 12-hour infusion of 10 microg/min (EPIC regimen)

Comparator

Abciximab 0.25-mg/kg bolus and a 12-hour infusion of 0.125 microg/kg/min (EPILOG regimen)

Outcome

Pharmacodynamics of abciximab (inhibition of ex vivo platelet aggregation and GP IIb/IIIa receptor blockade)surrogate

Abciximab exhibits continuous reequilibration among circulating platelets, providing prolonged platelet inhibition that exceeds the normal platelet life span.

Cite This Study

Mascelli et al. (1998) studied this question.

synapsesocial.com/papers/6a197856f2eb401dc7892222 https://doi.org/10.1161/01.cir.97.17.1680

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider